Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00079716 · ClinicalTrials.gov registry record · Phase 1

Study of SGN-40 in Patients With Refractory or Recurrent Multiple Myeloma

A Phase 1 study of Multiple Myeloma, sponsored by Seagen.

Completed
Registry status
Phase 1
Development phase
44
Enrollment target
5
Study locations

NCT00079716 is a Phase 1 study of Multiple Myeloma that has completed, run by Seagen. The registered enrollment target is 44 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (92% lower). The trial reports 5 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00079716, a Phase 1 study of Multiple Myeloma, has completed, sponsored by Seagen.

COMPLETED
Registry status
Phase 1
Development phase
44 participants
Enrollment target
5
Study locations

Study Summary

The purpose of this study is to determine the safety and activity of SGN-40 in a weekly dosage schedule as a single agent.

Conditions Studied

Multiple Myeloma

Interventions

  • DRUG SGN-40 (anti-huCD40 mAb)

Study Locations (5)

California

  • James R. Berenson M.D., Inc. - West Hollywood

Colorado

  • Rocky Mountain Cancer Center - Denver

Massachusetts

  • Dana Farber Cancer Institute - Boston

New York

  • Cornell University - New York

Ohio

  • The Cleveland Clinic - Cleveland

Trial Details

FieldValue
Enrollment Target 44 participants
Start Date 2004-03
Est. Completion 2007-11
Phase Phase 1

Sponsor

Seagen

84 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00079716

The ClinicalTrials.gov registry entry for NCT00079716 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (92% lower). The listed sponsor is Seagen, which has 84 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 1 intervention - of which SGN-40 (anti-huCD40 mAb) is the first listed.

NCT00079716 reports 5 study locations spanning 5 distinct geographic areas - top geographies include California, Colorado, Massachusetts.

Frequently Asked Questions

What is clinical trial NCT00079716 about?

NCT00079716 is a clinical study titled "Study of SGN-40 in Patients With Refractory or Recurrent Multiple Myeloma". The purpose of this study is to determine the safety and activity of SGN-40 in a weekly dosage schedule as a single agent.

What is the current status of trial NCT00079716?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 44 participants. The study started on 2004-03. Estimated completion is 2007-11.

What conditions does trial NCT00079716 study?

This clinical trial studies the following conditions: Multiple Myeloma.

What interventions are being tested in trial NCT00079716?

The interventions under investigation include: SGN-40 (anti-huCD40 mAb) (DRUG).

Who is sponsoring clinical trial NCT00079716?

This trial is sponsored by Seagen, which has 84 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00079716 being conducted?

This trial has 5 study locations across California, Colorado, Massachusetts, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Multiple Myeloma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Multiple Myeloma

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.